← IRONWOOD PHARMACEUTICALS INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $274.0m | $298.3m | $346.6m | $428.4m | $389.5m | $413.8m | $410.6m | $442.7m | $351.4m | $296.2m | |
| Cost of Revenue | $1.9m | $19.1m | $32.8m | $23.9m | $3.1m | $70.4m | $44.3m | $332.1m | $114.0m | $115.4m | |
| Gross Profit (Calculated) (derived) | $272.1m | $279.2m | $313.9m | $404.5m | $386.4m | $343.4m | $366.3m | $110.7m | $237.4m | $180.8m | |
| Operating expenses: | |||||||||||
| Operating Income (Loss) | ($51.9m) | ($77.4m) | ($238.9m) | $120.1m | $142.9m | $232.3m | $250.3m | ($945.4m) | $93.1m | $98.5m | |
| Additional Financial Items | |||||||||||
| Amortization of Intangible Assets | $981k | $6.2m | $8.1m | — | — | — | — | — | — | — | |
| Goodwill, Impairment Loss | — | $0 | $0 | $0 | $0 | — | — | — | — | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | — | — | — | — | $226.5m | $167.1m | $161.2m | |
| Income (Loss) from Continuing Operations, Per Basic Share | — | — | — | $0 | $1 | $3 | — | — | — | — | |
| Income (Loss) from Continuing Operations, Per Diluted Share | — | — | — | $0 | $1 | $3 | — | — | — | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | — | — | $108.9m | $200.7m | $252.4m | ($948.1m) | $65.2m | $70.0m | |
| Gain (Loss) on Derivative Instruments, Net, Pretax | $8.1m | ($3.3m) | ($8.7m) | $3.0m | ($6.1m) | ($1.2m) | $182k | $19k | — | — | |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | — | — | — | $58.9m | $106.2m | $528.4m | — | — | — | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | — | — | — | ($37.4m) | — | — | — | — | — | — | |
| Investment Income, Net | $1.2m | $2.1m | $3.0m | $2.9m | $1.5m | $726k | $9.5m | $19.0m | $4.5m | $4.1m | |
| Net Income (Loss) Attributable to Parent | ($81.7m) | ($116.9m) | ($282.4m) | $21.5m | $106.2m | $528.4m | $175.1m | ($1.0b) | $880k | $24.0m | |
| Net Income (Loss) Available to Common Stockholders, Basic | ($81.7m) | ($116.9m) | ($282.4m) | $21.5m | $106.2m | $528.4m | $175.1m | ($1.0b) | $880k | $24.0m | |
| Net Income (Loss) Attributable to Noncontrolling Interest | — | — | — | — | — | — | — | ($29.3m) | — | — | |
| Earnings Per Share, Basic | — | — | — | $0.14 | $0.67 | $3.26 | $1.13 | ($6.45) | $0.01 | $0.15 | |
| Earnings Per Share, Diluted | — | — | — | $0.14 | $0.66 | $3.21 | $0.96 | ($6.45) | $0.01 | $0.15 | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | 159.4m | 162.2m | 154.4m | 155.4m | 159.1m | 161.8m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | 160.7m | 164.4m | 186.3m | 155.4m | 160.1m | 163.0m | |
| Research and Development Expense | $139.5m | $148.2m | $166.5m | $115.0m | $88.1m | $70.4m | $44.3m | $116.1m | $111.4m | $95.1m | |
| Selling, General and Administrative Expense | $173.3m | $233.1m | $241.3m | $172.4m | $140.0m | $111.1m | $116.0m | $158.3m | $144.3m | $82.3m | |
| Other Nonoperating Income (Expense) | — | — | — | — | — | — | — | — | $640k | $193k | |
| Interest Expense (non-operating) | — | — | — | — | — | — | — | — | $33.0m | $32.7m | |
| Costs and Expenses | $325.8m | $375.7m | $585.5m | $308.3m | $246.6m | $181.5m | $160.3m | $1.4b | $258.3m | $197.6m | |
| Current Income Tax Expense (Benefit) | — | — | $0 | $0 | $2.7m | $5.5m | $11.6m | $10.9m | ($3.7m) | $5.2m | |
| Interest Expense | $39.2m | $36.4m | $37.7m | $36.6m | $29.5m | $31.1m | $7.6m | $21.6m | — | — | |
| Interest Expense, Debt | — | — | — | — | — | $31.1m | $7.6m | — | — | — | |
| Income Tax Expense (Benefit) | $0 | $0 | $0 | $0 | $2.7m | ($327.8m) | $77.4m | $83.5m | $64.3m | $46.0m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.